IceCure Medical Ltd (ICCM)
NASDAQ: ICCM · Real-Time Price · USD
0.6864
+0.0075 (1.10%)
At close: Dec 5, 2025, 4:00 PM EST
0.6826
-0.0038 (-0.55%)
After-hours: Dec 5, 2025, 6:21 PM EST
IceCure Medical Revenue
IceCure Medical had revenue of $850.00K in the quarter ending September 30, 2025, with 28.40% growth. This brings the company's revenue in the last twelve months to $2.98M, down -18.96% year-over-year. In the year 2024, IceCure Medical had annual revenue of $3.29M with 1.92% growth.
Revenue (ttm)
$2.98M
Revenue Growth
-18.96%
P/S Ratio
13.71
Revenue / Employee
$45,076
Employees
66
Market Cap
47.34M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.29M | 62.00K | 1.92% |
| Dec 31, 2023 | 3.23M | 144.00K | 4.67% |
| Dec 31, 2022 | 3.09M | -1.05M | -25.45% |
| Dec 31, 2021 | 4.14M | 270.00K | 6.98% |
| Dec 31, 2020 | 3.87M | 2.21M | 132.76% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ICCM News
- 1 day ago - IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes - PRNewsWire
- 17 days ago - IceCure Medical Ltd (ICCM) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 17 days ago - IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025 - PRNewsWire
- 18 days ago - IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer - PRNewsWire
- 22 days ago - IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification - PRNewsWire
- 24 days ago - IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025 - PRNewsWire
- 26 days ago - IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction - PRNewsWire
- 4 weeks ago - IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival - PRNewsWire